Problems in Detecting HER2 in Breast Cancer by Using Immunohistochemistry and Fluorescence in Situ Hybridization

doi:10.3870/j.issn.1672-8009.2025.06.012

Journal of Medical Molecular Biology ›› 2025, Vol. 22 ›› Issue (6): 612-616.doi: 10.3870/j.issn.1672-8009.2025.06.012

• Original Articles • Previous Articles Next Articles

Problems in Detecting HER2 in Breast Cancer by Using Immunohistochemistry and Fluorescence in Situ Hybridization

ZHANG Xinjuan¹, WEI Xiaoyun¹, LI Xiaofeng¹, LIU Xi¹, OU Da², KANG Yan³, ZHAO Xiao-ni¹, YANG Zhe¹, WANG Yuanyuan¹

¹Department of Pathology,First Affiliated Hospital of Xi’an Jiaotong University,Xi’an,710000,China
²Department of Pathology,Northwest Women’s and Children’s Hospital,Xi’an,710061,China
³Department of Pathology,Shenmu Hospital,Yulin,Shaanxi,719399,China

Received:2025-02-18 Online:2025-11-30 Published:2025-12-25
Contact: WANG Yuanyuan(E-mail:1051815925@qq.com)
Supported by:
International Scientific and Technological Cooperation and Exchange Program of Shaanxi Province(No.2016KW-001)

Abstract

Abstract: Objective To explore the problems of immunohistochemistry and fluorescence in situ hybridization in HER2 detection of breast cancer. Methods A total of 309 HER2 IHC 2+ breast cancer samples underwent FISH analysis,including 159 specimens submitted at our hospital in 2018,54 specimens between 2010 and 2012,and 96 specimens from external hospitals between 2016 and 2019. Results The positive rate of FISH test results for breast cancer HER2 IHC 2+ cases in 2018 was significantly lower than that of specimens from other hospitals and the hospital from 2010 to 2012. Conclusion Patients with breast cancer expected to undergo HER2-targeted therapy,particularly those from subordinate hospitals or diagnosed at an early stage,should be further tested using immunohistochemical analysis or FISH to guide precision medicine.

Key words: breast cancer, human epidermal growth factor receptor 2, immunohistochemistry, fluorescence in situ hybridization

CLC Number:

R737.9

ZHANG Xinjuan, WEI Xiaoyun, LI Xiaofeng, LIU Xi, OU Da, KANG Yan, ZHAO Xiao-ni, YANG Zhe, WANG Yuanyuan. Problems in Detecting HER2 in Breast Cancer by Using Immunohistochemistry and Fluorescence in Situ Hybridization[J]. Journal of Medical Molecular Biology, 2025, 22(6): 612-616.

References

[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[2] HAMILTON E,SHASTRY M,SHILLER S M,et al.Targeting HER2 heterogeneity in breast cancer[J].Cancer Treat Rev,2021,100:102286.
[3] MODI S,SAURA C,YAMASHITA T,et al.Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J].N Engl J Med,2020,382(7):610-621.
[4] SAURA C,OLIVEIRA M,FENG Y H,et al.Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with >/= 2 HER2-directed regimens:Phase III NALA trial[J].J Clin Oncol,2020,38(27):3138-3149.
[5] 吕丹,吴云,马飞.2021年乳腺癌治疗新进展[J].肿瘤综合治疗电子杂志,2022,8(01):85-93.
[6] YEO S K,GUAN J L.Breast cancer:Multiple subtypes within a tumor?[J].Trends Cancer,2017,3(11):753-760.
[7] PEROU C M,SORLIE T,EISEN M B,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
[8] 孙向洁,杨文涛.免疫组织化学在乳腺癌分子分型中的作用及目前存在的问题[J].中国癌症杂志,2019,29(03):161-165.
[9] HAMMOND M E,HAYES D F,DOWSETT M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer(unabridged version)[J].Arch Pathol Lab Med,2010,134(7):e48-e72.
[10] WOLFF A C,HAMMOND M E,HAYES D F.Re:predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria[J].J Natl Cancer Inst,2012,104(12):957-958.
[11] WOLFF A C,HAMMOND M E,HICKS D G,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J].J Clin Oncol,2013,31(31):3997-4013.
[12] WOLFF A C,HAMMOND M,ALLISON K H,et al.Human epidermal growth factor receptor 2 testing in breast cancer:American society of clinical oncology/college of american pathologists clinical practice guideline focused update[J].J Clin Oncol,2018,36(20):2105-2122.
[13] CUADROS M,VILLEGAS R.Systematic review of HER2 breast cancer testing[J].Appl Immunohistochem Mol Morphol,2009,17(1):1-7.
[14] 《乳腺癌HER2检测指南(2019)版》编写组.乳腺癌HER2检测指南(2019版)[J].中华病理学杂志,2019(03):169-175.
[15] 朱磊,潘颖,周毅,等.乳腺癌原发灶和复发及转移灶中ER、PR、HER-2、Ki67的变化及其临床意义[J].中国现代医生,2018,56(13):14-17.

Problems in Detecting HER2 in Breast Cancer by Using Immunohistochemistry and Fluorescence in Situ Hybridization

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	CUI Min, ZHANG Tong, SI Mengyuan, LIN Ying, XIE Wenjie, SUN Jirui. Oxysophocarpine Induces Apoptosis of Breast Cancer Cells by Inhibition of Nrf2/HO-1 Signaling Pathway [J]. Journal of Medical Molecular Biology, 2025, 22(6): 571-578.
[2]	SONG Yunjie, LIANG Jia, XU Bin, ZHANG Penghui, WEI Limin. Effect of circRNA VAPA/miR-377-3p/ZEB2 Axis on Paclitaxel Resistance of Breast Cancer [J]. Journal of Medical Molecular Biology, 2025, 22(6): 579-585.
[3]	WANG Yuanyuan, ZHAO Xiaoni, YANG Zhe, ZHANG Jiaojiao, XIA Nina, LI Xiaofeng, LIU Xi, WEI Xiaoyun. Clinical Significance of EGFR Expression and Amplification in Tongue Squamous Cell Carcinoma #br# [J]. Journal of Medical Molecular Biology, 2025, 22(5): 430-434.
[4]	FU Yuxing, PENG Qian, YANG Chaogang, . Expression and Clinical Prognostic Value of MCUR1 in Triple-negative Breast Cancer #br# [J]. Journal of Medical Molecular Biology, 2025, 22(3): 266-270.
[5]	ZHANG Lu, ZHANG Rui, LIU Jun, YANG Angang. GATA3 Inhibits Migration of Human Breast Cancer Cells by Regulating LIFR #br# [J]. Journal of Medical Molecular Biology, 2024, 21(4): 293-299.
[6]	JIANG Li, WANG Huihui, KE Longzhu, LI Gongzhuo, LUO Li. Effect of SRPK1 on Malignant Progression of Triple Negative Breast Cancer Cells by Activation of the PI3K / AKT Pathway #br# [J]. Journal of Medical Molecular Biology, 2024, 21(2): 161-165.
[7]	JI Peng , ZHAO Huashan , WANG Chen , LIU Shurong , MA Jianzeng . Effect of LncRNA BCYRN1 on Proliferation and Mobility of MCF-7 Breast Cancer Cells and Xenograft Growth in Mice [J]. Journal of Medical Molecular Biology, 2023, 20(5): 444-449.
[8]	ZHANG Jun, LI Jie, LI Xing, LI Gezi, ZHAO Chongru, CHEN Jiali, PENG Dawei, ZHANG Tianying. miR-205 Influences the Metastatic Activity of Triple Negative Breast Cancer Cells through JAK2 / STAT3 Signaling Pathway [J]. Journal of Medical Molecular Biology, 2023, 20(4): 310-315.
[9]	HE Yu, YUAN Zhipeng, LU Zhibin, LIAO Jingsheng, JIA Jun. LncRNA HOTAIR Regulates Paclitaxel Resistance in Breast Cancer Cells through miR-130a-3p / ABCC5 [J]. Journal of Medical Molecular Biology, 2023, 20(4): 316-323.
[10]	HU Chanyuan, YANG Hui, LI Sanrong. Expression of Serum Exosomal lncRNA HOTTIP in Breast Cancer Patients and Its Clinical Significance [J]. Journal of Medical Molecular Biology, 2022, 19(6): 501-506.
[11]	XU Yuchun, GAO Renkang. Expression of mir-342-3p in Breast Cancer Tissues and Its Correlation with Clinicopathological Features and Long-Term Prognosis in Patients [J]. Journal of Medical Molecular Biology, 2022, 19(4): 307-313.
[12]	HUANG Guoding, PAN Minli, LU Hongquan, LV Qiongxiu. Analysis of BRCA1 / 2 Gene Mutations in Breast Cancer Patients in Western Hainan [J]. Journal of Medical Molecular Biology, 2022, 19(4): 314-319.
[13]	JIA Qin, LIN Boning, GU Yunxue. Effect of ATR Inhibitor Combined with Carboplatin Treatment on the Growth of Breast Cancer Xenografts and the Expression of BRG1, RAD51, PALB2 in Nude Mice [J]. Journal of Medical Molecular Biology, 2022, 19(4): 338-343.
[14]	BI Yang, WEN Xinling, DU Hailiang, ZHOU Rongshen. Lidocaine Inhibits the Activity and Drug Resistance of Human Breast Cancer Cells by Down-regulating ABCG2 [J]. Journal of Medical Molecular Biology, 2022, 19(1): 33-40.
[15]	JI Huiqin, YANG Chaogang, DENG Shuang, ZHONG Jun. Expression of Keratin 17 in Colorectal Cancer and Its Clinical Prognostic Value [J]. Journal of Medical Molecular Biology, 2022, 19(1): 56-61.